Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02249936 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations

A Phase 1 study of Healthy, sponsored by Ardelyx.

Completed
Registry status
Phase 1
Development phase
18
Enrollment target
1
Study location

NCT02249936 is a Phase 1 study of Healthy that has completed, run by Ardelyx. The registered enrollment target is 18 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02249936, a Phase 1 study of Healthy, has completed, sponsored by Ardelyx.

COMPLETED
Registry status
Phase 1
Development phase
18 participants
Enrollment target
1
Study location

Study Summary

The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of different formulations of AZD1722 in healthy male and female subjects taking Omeprazole.

Conditions Studied

Interventions

  • DRUG Omeprazole
  • DRUG AZD1722

Study Locations (1)

Nebraska

  • ICON Development Solutions - Omaha

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2013-02
Est. Completion 2013-02
Phase Phase 1

Sponsor

Ardelyx

25 total trials

What the Registry Record Tells You About NCT02249936

The ClinicalTrials.gov registry entry for NCT02249936 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Omeprazole is the first listed.

NCT02249936 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.

Frequently Asked Questions

What is clinical trial NCT02249936 about?

NCT02249936 is a clinical study titled "A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations". The study is designed to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of different formulations of AZD1722 in healthy male and female subjects taking Omeprazole.

What is the current status of trial NCT02249936?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-02. Estimated completion is 2013-02.

What conditions does trial NCT02249936 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02249936?

The interventions under investigation include: Omeprazole (DRUG), AZD1722 (DRUG).

Who is sponsoring clinical trial NCT02249936?

This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02249936 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.